Print Page  |  Close Window

SEC Filings

6-K
TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form 6-K on 08/03/2017
Entire Document
 


Table of Contents

Specialty Medicines Revenues

Our revenues from specialty medicines in the first six months of 2017 were $4.1 billion, a decrease of 8% compared to the first six months of 2016. In the United States, our specialty medicines revenues were $3.0 billion, a decrease of 12% compared to the first six months of 2016. Specialty medicines revenues in Europe were $0.9 billion, an increase of 6% compared to the first six months of 2016. In local currency terms, specialty medicines revenues in Europe increased 11%. Specialty medicines revenues in ROW were $200 million, an increase of 20% compared to first six months of 2016. In local currency terms, specialty medicines revenues in ROW increased 21%.

Specialty Medicines Revenues Breakdown

The following table presents revenues by therapeutic area and key products for our specialty medicines segment for the six months ended June 30, 2017 and 2016:

 

     Six Months Ended June 30,      Percentage Change  
     2017      2016      2017 - 2016  
     U.S. $ in millions         

CNS

   $ 2,296      $ 2,738        (16 %) 

Copaxone®

     1,993        2,147        (7 %) 

Azilect®

     94        221        (57 %) 

Nuvigil®

     31        154        (80 %) 

Respiratory

     626        679        (8 %) 

ProAir®

     244        308        (21 %) 

QVAR®

     205        250        (18 %) 

Oncology

     550        602        (9 %) 

Treanda® and Bendeka®

     320        362        (12 %) 

Women’s Health

     239        227        5

Other Specialty*

     374        177        111
  

 

 

    

 

 

    

Total Specialty Medicines

   $ 4,085      $ 4,423        (8 %) 

 

* Includes aggregate payments of $150 million related to the Ninlaro® transaction in the first half of 2017.

Central Nervous System

In the first six months of 2017, our CNS sales were $2.3 billion, a decrease of 16% compared to the first six months of 2016.

Copaxone® sales in the first six months of 2017 were $2.0 billion, a decrease of 7% compared to the first six months of 2016.

Copaxone® revenues in the United States, in the first six months of 2017 were $1.6 billion, a decrease of 9% compared to the first six months of 2016.

Our Copaxone® revenues outside the United States were $368 million during the first six months of 2017, a decrease of 1% compared to the first six months of 2016, or an increase of 3% in local currency terms.

Azilect® sales in the first six months of 2017 were $94 million, a decrease of 57% compared to the first six months of 2016.

Nuvigil® sales in the first six months of 2017 were $31 million, a decrease of 80% compared to the first six months of 2016.

Respiratory Products

In the first six months of 2017, revenues from our specialty respiratory products were $626 million, a decrease of 8% compared to the first six months of 2016.

ProAir® revenues in the first six months of 2017 were $244 million, a decrease of 21% compared to the first six months of 2016.

 

59